ZEALAND PHARMA’s (NASDAQ:ZEAL) quiet period will end on Monday, September 18th. ZEALAND PHARMA had issued 4,375,000 shares in its IPO on August 9th. The total size of the offering was $78,181,250 based on an initial share price of $17.87. During ZEALAND PHARMA’s quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

A number of equities research analysts have recently commented on the company. Morgan Stanley assumed coverage on ZEALAND PHARMA in a research note on Tuesday, September 5th. They set an “overweight” rating and a $28.00 target price on the stock. Needham & Company LLC assumed coverage on ZEALAND PHARMA in a research note on Tuesday, September 5th. They set a “buy” rating and a $26.00 target price on the stock. Finally, Guggenheim assumed coverage on ZEALAND PHARMA in a research note on Tuesday, September 5th. They set a “buy” rating and a $28.00 target price on the stock.

TRADEMARK VIOLATION NOTICE: “ZEALAND PHARMA’s Quiet Period Will End on September 18th (NASDAQ:ZEAL)” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/09/11/zealand-pharmas-quiet-period-will-end-on-september-18th-nasdaqzeal.html.

Shares of ZEALAND PHARMA (NASDAQ ZEAL) opened at 20.12 on Monday. The company has a 50-day moving average price of $18.30 and a 200 day moving average price of $18.30. ZEALAND PHARMA has a one year low of $16.07 and a one year high of $20.37. The stock’s market cap is $618.09 million.

Receive News & Ratings for ZEALAND PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.